Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nautilus Biotechnology, Inc. - Common Stock (NQ: NAUT )

0.6908 -0.0222 (-3.11%)
Streaming Delayed Price Updated: 12:36 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 107,468
Open 0.7044
Bid (Size) 0.6908 (38)
Ask (Size) 0.6909 (2)
Prev. Close 0.7130
Today's Range 0.6900 - 0.7119
52wk Range 0.6600 - 3.090
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire

Performance

YTD
-59.12%
-59.12%
1 Month
-24.95%
-24.95%
3 Month
-65.46%
-65.46%
6 Month
-74.60%
-74.60%
1 Year
-71.22%
-71.22%

More News

Read More
Earnings Scheduled For February 27, 2025
Via Benzinga
Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
NAUT Stock Earnings: Nautilus Biotechnology Beats EPS for Q2 2024
Via InvestorPlace
Nautilus Biotechnology Reports Second Quarter 2024 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
NAUT Stock Earnings: Nautilus Biotechnology Beats EPS for Q1 2024
Via InvestorPlace
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
From Nautilus Biotechnology Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award
From Nautilus Biotechnology Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.